Education

Why Intellia Therapeutics Stock Is a “Strong Buy”

Apart from artificial intelligence (AI) and cryptocurrency, genome editing research and development has long been a popular stock on Wall Street. Intellia Therapeutics (NASDAQ:NTLA) just earned a critical regulatory green light in this field, propelling Intellia Therapeutics stock higher. Analysts rate the biotechnology firm as a “Strong Buy,” but it

Another Case of So Bad, They’re Good: Kohl’s Earnings

Kohl’s Corporation (NYSE:KSS) reported a dismal Q4 2022 earnings report, missing top and bottom lines and decreasing its full-year 2023 expectations. Kohl’s missed practically every metric, with shares initially falling in the post-market but rebounding the next day, perplexing investors. Because the market is always looking ahead, stocks tend to

Get Your Free Actionable Trading Report Each DaySubscribe to the
What’s On Finance
mailing list and get interesting stuff and updates to your email inbox.